Observational Study Protocol: LIVER-R - LIVER-R

Study identifier:D419CR00035

ClinicalTrials.gov identifier:NCT06252753

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

An Observational Multi center Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers

Medical condition

Hepatobiliary Cancers

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

2490

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 20 Dec 2023
Estimated Primary Completion Date: 13 Dec 2029
Estimated Study Completion Date: 13 Dec 2029

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

ICON plc

Inclusion and exclusion criteria